The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Clinical implications of HER2 in GI cancers
Daniel Catenacci, MD, University of Chicago, Chicago, IL, discusses the clinical implications of HER2 in gastrointestinal cancers as discussed at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting and highlights the role of HER2-targeted agents in gastroesophageal cancer as well as molecular heterogeneity in HER2 expression seen in gastrointestinal tumours which may result in differences in response to HER2 agents. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Daniel Catenacci, MD has received support/funding from Genentech/Roche, Eli Lilly, Merck, Daiichi Sankyo, BMS, Ono, Five Prime, Seattle Genetics, Amgen, Taiho, Astellas, Gritstone, Pieris, Zymeworks, Basilea, QED, Arcus, Foundation Medicine, Tempus, Guardant Health, Archer, and Natera.
